A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Livoletide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Alize Pharma; Millendo Therapeutics SAS
- 20 Dec 2017 According to an Alize Pharma media release, Alize Pharma SAS was acquired by Millendo Therapeutics and subsequently changed its named to Millendo Therapeutics SAS.
- 29 Oct 2015 Results published in an Alize Pharma media release.
- 29 Oct 2015 Status changed from active, no longer recruiting to completed according to an Alize Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History